Objective: To assess whether secukinumab treatment in patients with active psoriatic arthritis (PsA) is associated with sustained inhibition of radiographic progression.
Our paper explores the clinical trial evidence available for secukinumab to examine its safety and efficacy as a therapeutic agent for the treatment of PsA.
Background: Hyperactivity of the IL-23/IL-17 axis is central to plaque psoriasis pathogenesis. Secukinumab, a fully human mAb that selectively inhibits IL-17A, is approved for treatment of psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Background: Interleukin 17A is a proinflammatory cytokine that is implicated in the pathogenesis of psoriatic arthritis. We assessed the efficacy and safety of subcutaneous secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis.
Novartis announced that results from the pivotal Phase III FUTURE 1 study for secukinumab in psoriatic arthritis (PsA) were published...
Novartis announced new results for Cosentyx (secukinumab) showing no further progression in joint damage in 84% of patients with psoriatic...
Psoriasis is a multi-systemic chronic inflammatory disease that affects about 1.5-3% of the general population, of which almost 20% suffer from a moderate-severe form.
Novartis announced that the European Commission (EC) has approved Cosentyx (secukinumab) for the treatment of people living with psoriatic arthritis...
While there are several commercially available treatment options for psoriasis and psoriatic arthritis, there remains a large number of individuals who are refractory to current modalities.
The UK's National Institute for Health and Care Excellence is supporting use of Cosentyx (secukinumab), from Novartis, alone, or in...